GlassScriptPhysician profile
Jason Ice
NPI 1467951863
$11,918.55
in general payments reported to CMS, 2019-2025
42 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.58 · 2021: $1,892 · 2022: $3,821 · 2023: $2,857 · 2024: $1,481 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,186.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,449.99 | 2021-2025 | |
| Novo Nordisk INC | $1,256.43 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $804.25 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $753.86 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $686.73 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $655.59 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $651.44 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $610.54 | 2021-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $563.13 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.43 | 2021-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $387.98 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $269.73 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $256.78 | 2021-2023 | Airduo Digihaler |
| Sanofi-Aventis U.S. LLC | $201.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $183.87 | 2020-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $178.89 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $164.30 | 2021 | |
| Axsome Therapeutics, INC. | $156.13 | 2023-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $156.12 | 2023-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $151.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $128.39 | 2023-2025 | Gvoke Hypopen |
| Amgen INC. | $107.30 | 2021-2025 | Otezla, Repatha, Prolia |
| Phathom Pharmaceuticals, INC. | $92.06 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $65.72 | 2021-2025 | |
| Astellas Pharma US INC | $61.18 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $52.97 | 2021-2023 | |
| Amarin Pharma, INC. | $51.72 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $49.76 | 2025 | Rexulti |
| Madrigal Pharmaceuticals | $49.52 | 2025 | Rezdiffra |
| Dynavax Technologies Corporation | $46.43 | 2022-2024 | Heplisav-B |
| Dexcom, INC. | $38.97 | 2023-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $31.79 | 2021 | |
| Atricure, INC. | $30.20 | 2023 | |
| Idorsia Pharmaceuticals US INC | $30.20 | 2022-2023 | Quviviq |
| Lundbeck LLC | $20.64 | 2025 | Rexulti |
| Ucb, INC. | $20.18 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $17.86 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.84 | 2023 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $14.65 | 2022 | |
| Currax Pharmaceuticals LLC | $14.43 | 2022 | |
| Ibsa Pharma INC. | $13.57 | 2022 | |
| Sobi, INC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.